Three susceptible loci associated with primary open-angle glaucoma identified by genome-wide association study in a Japanese population

Nakano M., Ikeda Y., Taniguchi T., Yagi T., Fuwa M., Omi N., Tokuda Y., Tanaka M., Yoshii K., Kageyama M., Naruse S., Matsuda A., Mori K., Kinoshita S., Tashiro K.

2009
Proceedings of the National Academy of Sciences of the United States of America

View publication

Therapeutic Area

Glaucoma
Categories

Disease understanding (epidemiology, diagnosis, QoL, Biomarkers…)

Affiliations

Department of Genomic Medical Sciences, Kyoto Prefectural University of Medicine, Kamigyo-ku, Kyoto 602-8566, Japan; Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan; Research and Development Center, Santen Pharmaceutical Co., Ltd., 8916-16 Takayama-cho, Ikoma, Nara 630-0101, Japan

Related Publications

Long-term safety and efficacy of sepetaprost, with or without timolol, in patients with open-angle glaucoma or ocular hypertension: results from the randomised, phase 3 ANGEL-J2 study

Inatani M., Tone Y., Ikeda T., Angeles R.

Efficacy and safety of sepetaprost in patients with primary open-angle glaucoma or ocular hypertension: results from the randomised, phase 3 ANGEL-J1 study

Inatani M., Kanamori A., Inai M., Ikeda T., Angeles R.

Clinical outcomes of Preserflo MicroShunt implant procedure in open‑angle glaucoma patients – a 1000 eyes case-series; including subanalysis of combined cataract-glaucoma surgery and standalone surgery in pseudophakic eyes

Klabe, K.; Werth, J.P.; Kaymak, H. ; Fricke, A.

View all Glaucoma publications